Glucagon-like peptide-1 receptor imaging with [Lys^{40}(Ahx-HYNIC-^{99m}Tc/EDDA)NH_2]-Exendin-4 for the diagnosis of recurrence or dissemination of medullary thyroid cancer : a preliminary report by Pach, Dorota et al.
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2013, Article ID 384508, 6 pages
http://dx.doi.org/10.1155/2013/384508
Research Article
Glucagon-Like Peptide-1 Receptor Imaging with
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-Exendin-4 for the
Diagnosis of Recurrence or Dissemination of Medullary Thyroid
Cancer: A Preliminary Report
D. Pach,1 A. Sowa-Staszczak,1 A. Jabrocka-Hybel,1 A. StefaNska,1 M. Tomaszuk,1
R. MikoBajczak,2 B. Janota,2 M. Trofimiuk-Müldner,1
E. Przybylik-Mazurek,1 and A. Hubalewska-Dydejczyk1
1 Department of Endocrinology, Jagiellonian University Medical College, Kopernika 17, 31-501 Krakow, Poland
2 Radioisotope Center POLATOM, National Centre for Nuclear Research, 05-400 Otwock, Poland
Correspondence should be addressed to A. Hubalewska-Dydejczyk; alahub@cm-uj.krakow.pl
Received 28 November 2012; Revised 14 February 2013; Accepted 13 March 2013
Academic Editor: Eleonore Fröhlich
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Introduction. Epidemiological studies on medullary thyroid cancer (MTC) have shown that neither a change in stage at diagnosis
nor improvement in survival has occurred during the past 30 years. In patients with detectable serum calcitonin and no clinically
apparent disease, a careful search for local recurrence, and nodal or distantmetastases, should be performed. Conventional imaging
modalities will not show any disease until basal serum calcitonin is at least 150 pg/mL. The objective of the study was to present
the first experience with labelled glucagon-like peptide-1 (GLP-1) analogue [Lys40(Ahx-HYNIC-99mTc/EDDA)NH
2
]-exendin-4 in
the visualisation of MTC in humans.Material and Method. Four patients aged 22–74 years (two with sporadic and two with MEN2
syndrome-related disseminated MTC) were enrolled in the study. In all patients, GLP-1 receptor imaging was performed. Results.
High-quality images were obtained in all patients. All previously known MTC lesions have been confirmed in GLP-1 scintigraphy.
Moreover, one additional liver lesion was detected in sporadic MTC male patient. Conclusions. GLP-1 receptor imaging with
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH
2
]-exendin-4 is able to detect MTC lesions. GLP-1 scintigraphy can serve as a confirmatory
test in MTC patients, in whom other imaging procedures are inconsistent.
1. Introduction
Medullary thyroid cancer (MTC) is a neuroendocrine neo-
plasm arising from the parafollicular cells, or C cells, of the
thyroid. It accounts for nearly 5–10%of thyroidmalignancies.
In nearly all MTC cases, cancer cells secrete calcitonin, a spe-
cific and highly sensitive biomarker—its measurement plays
an important role in diagnosis and postoperative followup of
patients [1–3]. The majority of MTCs are sporadic, but up to
25% of all cases result from a germ-line activating mutation
of the RET protooncogene [4, 5]. Hereditary MTCs occur
in the setting of the multiple endocrine neoplasia (MEN)
syndrome type 2 (2A or 2B) or as familial MTC (FMTC)—
a variant of MEN2A syndrome. The most common form
of hereditary MTC is MEN 2A (approximately 80–90% of
patients with hereditary MTC). Overall, the prognosis for
patients with MTC is good. The 10-year survival rate is
75–85%. Approximately half of the MTC patients present
with disease limited to the thyroid gland with a 10-year
survival rate of 95.6%. One-third of patients present with
locally invasive tumour or clinically apparent spread to the
regional lymph nodes. Patients with regional disease have
a 5-year overall survival rate of 75.5%. Recurrent disease
develops in approximately 50% of patients with MTC [1, 6].
Neck ultrasound should be performed as a part of the initial
evaluation of each patient with newly diagnosed MTC. Fine-
needle aspiration (FNA) cannot always distinguish MTC
based on the appearance of tumor cells alone, so the diagnosis
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is typically confirmed by immunostaining or by the mea-
surement of calcitonin level in the washout fluid from FNA.
This latter technique appears to be even more sensitive than
cytology with immunohistochemistry [1].
The primary treatment for MTC is surgical resection.
Total thyroidectomy with complete resection of central
neck, paratracheal, and upper mediastinal lymph nodes is
frequently needed. Currently, surgical excision is the only
effective treatment for MTC. Patients who have clinically
apparent disease are best treated with a minimum of total
thyroidectomy and bilateral central neck dissection [7, 8].
Followup should start 2-3 months postoperatively by obtain-
ing new baseline calcitonin levels. An undetectable basal
serum calcitonin level is a strong predictor of complete
remission. Patients with biochemical remission after initial
treatment have only a 3% risk of recurrence during long-term
followup [1, 2].
Calcitonin and stimulated calcitonin levels are very
sensitive ways for detecting either residual or recurrent
disease. When the postoperative calcitonin level is elevated,
a careful search for metastases has to be performed prior to
surgical exploration. Imaging techniques will not show any
disease until basal serum calcitonin level exceeds 150 pg/mL.
In patients with serum calcitonin lower than 150 pg/mL,
localization of the disease should be focused on careful
examination using neck ultrasound because such calcitonin
levels are usually associated with locoregional disease. The
optimal timing of this followup should be based on calcitonin
and CEA (carcinoembryonic antigen) doubling times (DT),
which are strongly correlatedwith disease progression [9–12].
There are some MTC patients in whom, despite of the
elevated postoperative calcitonin levels and/or abnormal
results of the pentagastrin test, there is no evidence of the
disease in conventional imaging techniques. Prolonged delay
in disease localization usually results in treatment failure
even if the tumor recurrence/residue is finally detected.
Molecular imaging techniques, based on the development of
tracers which are taken up by MTC cells or are bound to
MTC-specific receptors, could be applied in such group of
patients. Therefore, besides the use of those well-known and
commonly used radiotracers, such as labelled somatostatin
analogues or mIBG, there are still clinical trials performed
to find more specific and sensitive substances. Glucagon-like
peptide 1 (GLP-1) labelled analogues have been considered
as a promising tool for visualization of MTC. Physiologically
GLP-1 (glucagon-like peptide-1) receptors have been found in
organs like pancreas, blood vessels, stomach, or parafollicular
C cells. Their expression is also observed in different types
of neoplasms including MTC [13]. Both 111In-labeled GLP-
1 analogue ([Lys40(Ahx-DTPA-111In)NH
2
]-exendin-4 and
68Ga/99mTc labeled GLP-1 analogue exendin-4 were success-
fully used in patients with insulinoma [14–16]. 99mTc labelled
GLP-1 analogue, may improve the quality of images and radi-
ation safety for patients and the staff due to many procedural
advantages related to the isotope physical properties.
The question of the management of patients with local
recurrence and contraindications to surgical intervention
or patients with dissemination of the disease has not been
solved. Those patients are left with few therapeutic choices.
Chemotherapy is of limited value. [17]. External beam radi-
ation therapy (EBRT) may be used only to control local
disease [7, 8]. Serum calcitonin and CEA concentrations
do not normalize after EBRT, but long-term stabilization
may be achieved. Patients with metastatic disease can have
debilitating symptoms from calcitonin excess and therefore
may benefit from medical treatment with somatostatin ana-
logues. Since MTC cells express somatostatin receptors, a
radionuclide-targeted therapywith labelled octreotide and its
derivates is another therapeutic option [17, 18].
Molecular-targeted therapy is yet another therapeutic
strategy inMTC.With the discovery of the ret protooncogene
and its integral role in the pathogenesis of MTC, a new
class of therapeutics—tyrosine kinase inhibitors—has been
developed [17, 19, 20]. It is necessary to develop other
alternative therapeutic strategies to control tumour growth,
possibly through interference with various cellular signalling
pathways [17, 19, 20].
The aim of the paper is to present the first experi-
ence of our department with the new radiopharmaceuti-
cal [Lys40(Ahx-HYNIC-99mTc/EDDA)NH
2
]-exendin-4 as a
diagnostic tool in patients with suspected or confirmed
recurrence or dissemination of MTC and to compare its
performance with conventional imaging methods.
2. Material
Four patients (1 female, 3 males, aged 22–74 years) were
enrolled in the study. In all of them, recurrence or dissem-
ination of MTC was suspected, based on previous imaging
results and elevated calcitonin levels. In all patients, neck
ultrasound was performed with fine-needle aspiration biopsy
of suspected lesions in 3 cases. In two patients, neck and chest
computed tomography (CT) and in one case abdominal CT
were also performed. All subjects underwent somatostatin
receptor scintigraphy (SRS).
Patient 1 (J.S.). Patient with sporadic MTC underwent total
thyroidectomy with complete lymph nodes resection in the
central neck and paratracheal compartment in 2004. In 2009,
based on results of CT and SRS, patient was diagnosed
with liver metastases and qualified to the peptide receptor
radionuclide therapy (PRRT). Patient received 13.32GBq
(360mCi) of 90Y-DOTA-TATE. Treatment led to the sta-
bilization of the disease. GLP-1 receptor imaging was per-
formed to compare results with standard imaging procedures
(US, CT and SRS).
Patient 2 (S.S.). Patient with sporadic medullary cancer
underwent total thyroidectomy with neck lymph nodes
resection in 2003. In 2008, based on elevated calcitonin levels,
neck ultrasound, fine-needle aspiration biopsy, neck and
chest CT, and SRS dissemination to the neck and mediastinal
lymph nodes were confirmed. Patient was disqualified from
the surgery. Patient received 14.8GBq (400mCi) 90Y-DOTA-
TATE in 2008, which resulted in the stabilization of the
disease. GLP-1 receptor imaging was performed to compare
results with conventional imaging methods (US, CT, and
SRS).
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Table 1: Patients clinical data.
Initial Age Sex Diagnosis Genetic CT SRS Diff. studies GLP-1
J.S. 74 M Dissem Sporadic + + US− +
S.S. 70 M Dissem Sporadic + + US+ +
K.G. 22 M Recurr MEN 2A na − US+ +
Z.P. 60 F Dissem MEN 2B + − US+ +
∗F/M: female/male, –: negative result, +: positive result, na: not available, recur: recurrence, and dissem: dissemination.
This patient has also been diagnosed with chronic lym-
phocytic leukemia, diagnosed and operated for colon cancer
in 2009, and metaplasia and dysplasia of the urinary bladder
in 2010. In 2011 liver metastases from the colon cancer were
diagnosed and patient was qualified to chemotherapy.
Patient 3 (K.G.). Patient with MEN 2A syndrome underwent
total thyroidectomy with neck lymph node resection in 2001.
In 2009, abnormal pentagastrin test results were observed,
but imaging studies (which ones) did not detect any lesions.
In 2010, patient underwent bilateral adrenalectomy due to
pheochromocytoma. In 2011, hypoechoic lesion on the left
side of the neck u was revealed by ultrasound, but the biopsy
was negative. Thyroid scintigraphy with 99mTc and 131I were
positive, but SRS was negative. The GLP-1 receptor imaging
was ordered to facilitate discrimination between the thyroid
remnant and MTC recurrence.
Patient 4 (Z.P.). Patient with MEN 2B syndrome underwent
total thyroidectomy with neck lymph node resection in 1990,
followed by repeated surgery due to local recurrence in 1996.
In 1993 patient underwent right adrenal and in 1997 left
adrenal adrenalectomy due to pheochromocytoma. Based on
chest CT, patient was diagnosed with lung metastases and
local recurrence. SRS was negative. GLP-1 receptor imaging
was ordered to confirm MTC recurrence in patient with
discrepant results of other diagnostics images (positive CT,
but negative SRS).
The detailed patient data are summarized in Table 1.
All patients gave their written informed consent to the
local Medical College Ethics Committee which approved
protocol.
3. Methods
3.1. GLP-1 Analogue Scintigraphy. Patients were on a liquid
diet for 1 day before the beginning of the examination and
fasted on the day of the tracer injection. Each of them was
carefully checked for any adverse reactions. Due to natural
activity of GLP-1 (stimulation of insulin secretion), blood
pressure and glucose values were monitored before and after
injection of the compound at several time points.
3.2. Preparation of [Lys40(Ahx-HYNIC-99𝑚Tc/EDDA)NH
2
]-
Exendin-4. Technetium-99m labelled [Lys40(Ahx-HYNIC/
EDDA)NH
2
]-exendin-4 was obtained from lyophilized kits
prepared by the Institute of Atomic Energy, Radioisotope
Center POLATOM. Exendin-4 (20𝜇g) was modified C-
terminally with Lys40-NH
2
, where the lysine side chain
was conjugated with Ahx-HYNIC (Ahx is aminohexanoic
acid). Tricine and EDDA as coligands for 99mTc were added.
The radiopharmaceutical preparation was carried out in the
Nuclear Medicine Unit of the Endocrinology Department,
CracowUniversityHospital andwas performedunder aseptic
conditions. Two-vial freeze-dried kits were used for radi-
olabelling with 0.3–1.5mL pf 99Mo/99mTc generator eluate
(0.37–1.85GBq) followed by 20min incubation at 80∘C. The
TLC (thin layer chromatography) method was used for
assessing the radiochemical purity of the compound. The
mean injected activity was 740MBq.
3.3. Imaging Technique. GLP-1 receptor imaging with the
use of Lys40(Ahx-HYNIC-99mTc/EDDA)NH
2
]-exendin-4
was performed at the Nuclear Medicine Unit of the
Endocrinology Department in the University Hospital
in Cracow. At the beginning, images were acquired with
a dual-head, large field of view E.CAM gamma camera
with low-energy high-resolution (LEHR) collimators
(Siemens Healthcare, 2000). From 2010 all examinations
were performed with the use of Symbia TruePoint T16 hybrid
system also with LEHR collimators (Siemens Healthcare,
2007).
SPECT studies were performed at 2 time points, between
3-4 h and 5-6 h after the injection of the tracer. The
SPECT examinations were done with 128 × 128 matrix, 64
images, 30 sec per image, step and shoot mode, noncircu-
lar orbit and dual-energy window for scatter correction.
The acquired data were reconstructed using OSEM Flash
3D iterative reconstruction method with 8 subsets and 10
iterations. After the installation of the new hybrid device
in the unit, SPECT/CT studies were carried out in all next
patients with the same settings for the SPECT part of the
study.
In all cases low-dose CT imaging was performed for
the attenuation correction and a improved localization of
pathological uptake of the tracer.
The obtained images were assessed by the experienced
nuclear medicine specialist.
4. Results
The average radiochemical purity of the administered com-
pound, prepared according tomanufacturer’s instruction and
determined by TLC, was higher than 90%.
The quality of obtained Lys40(Ahx-HYNIC-99mTc/
EDDA)NH
2
]-exendin-4 images was assessed by the nuclear
medicine physician as very good.
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Figure 1: The positive results of GLP-1 receptor imaging in a 74-year-old patient (J.S.) with sporadic MTC; pathological uptake of the tracer
in liver metastases is visualized. (a) Axial slices and (b) coronal slices.
In all patients results of scintigraphy with [Lys40(Ahx-
HYNIC-99mTc/EDDA)NH
2
]-exendin-4 corresponded to the
results of previously performed imaging examinations.
In the first patient (J.S.) 99mTc-GLP-1 receptor scintig-
raphy revealed in homogenous liver uptake and focally
increased tracer uptake at the location of previously con-
firmed liver metastases (Figure 1). Moreover, an additional
liver lesion not seen on SRS, was detected. Patient 1 is still
available for followup with stable disease after PRRT.
In the second patient (S.S.), 99mTc-GLP-1 receptor scintig-
raphy performed after PRRT revealed small focal uptake in
the neck. The image was comparable with SRS findings.
In the patient K.G. (patient 3), 99mTc-GLP-1 receptor
scintigraphy showed focal tracer uptake at the location of the
ultrasonographically detected lesion on the left side of the
neck. The patient was further qualified for the surgery.
In the patient Z.P. (patient 4), 99mTc-GLP-1 receptor
scintigraphy revealed tracer uptake at the location of the
neck and chest lesions seen on CT. However, patient was
disqualified from surgery due to heart failure.
No adverse reactions were observed after tracer injection.
5. Discussion
MTC is still one of themost challenging endocrine cancers for
both physicians and patients. In some MTC patients, despite
of the elevated postoperative calcitonin levels and/or abnor-
mal results of the pentagastrin test, there is no evidence of the
disease in standard imaging procedures. Therefore searching
for new targets for radioisotope diagnostics is warranted.
99mTc(V)-dimercaptosuccunic acid (DMSA) was considered
by many authors the agent of choice in the postoperative
work-up of MTC. Sensitivities ranging from 50% up to 85%
have been reported in patients with primary and recurrent
MTC using planar scans. SPECT has increased the sensitivity
of lesion detection. Shahram reported that 99mTc(V)-DMSA
had 91% sensitivity and 75% specificity for the detection of
lung MTC compared to serum calcitonin as gold standard
[21]. Another diagnostic modality is scintigraphy with 99mTc-
MIBI. Overall sensitivity and specificity of this agent range
from 36% to 89% and 89% to 100%, respectively [22]. Uğur
et al. have compared the sensitivity of 99mTc-MIBI, 201Tl,
and 99mTc(V)-DMSA and shown them to be 47%, 19%, and
95%, respectively [23]. MIBG labelled with 123I or 131I, in
spite of its high specificity (>95%), is of little clinical utility
with a reported sensitivity of 30% [24]. Results from imaging
with monoclonal antibodies including 123I-, 131I-, and 111In-
labelled CEA, both whole antibody and fragments, and
111In-anticalcitionin antibody varied, ranging from 0% for
anticalcitionin antibody to 78% for 131I-anti-CEA antibody
[25]. Results of somatostatin receptor scintigraphy (SRS)
using an octreopeptides labeled with either 111In-DTPA
or 99mTc-EDDA/HYNIC in MTC patients reported in the
literature have been also extremely variable. The overall sen-
sitivity of 111In-pentetreotide scintigraphy for the detection
of MTC varies between 35 and 70% in different studies.
Krenning et al. reported sensitivity of 65% in detecting MTC
lesions by octreoscan, although the sensitivity was lower for
liver metastases as a result of nonspecific hepatic uptake
[26]. According to other authors, scintigraphy with 111In-
DTPA-octreotide has shown a sensitivity of 50–75%, that is
higher than radiolabelled MIBG [27] and similar or slightly
superior to 99mTc(V)-DMSA [28]. 18FDG-PET was more
sensitive especially in detecting cervical, supraclavicular, and
International Journal of Endocrinology 5
mediastinal lymph nodes, but failed to detect small lesions in
the lungs and liver [29]. However, other studies have shown
a lower sensitivity of 18FDG-PET when compared with CT
[30]. Data from the study by Ong and coworkers suggested
that 18FDG-PET is useful mainly in patients with calcitonin
levels exceeding 1000 pg/mL (78% sensitivity), whereas it
has limited value in patients with calcitonin levels below
500 pg/mL (20% sensitivity) [31]. Preliminary data suggest
that 18F-L-dihydroxyphenylalanine (L-DOPA) PETmay pro-
vide a better lesion detection than 18F-FDG for MTC lesions.
Beheshti et al. observed that 18F-DOPA correctly visualized
81% of MTC lesions compared to 58% detected with 18F-
FDG [32]. Hoegerle et al. reported an overall sensitivity of
63% for 18F-DOPA PET in 11 patients with MTC, which was
lower than that observed with CT/MRI (it should be stressed
that authors used a stand-alone PET system and not a hybrid
PET/CT system), but higher than those observed with 18F-
FDG and 111In-DTPA-octreotide scan [33].
Above-mentioned diversity of sensitivity and specificity
of different imaging modalities used in patients with sus-
picion of recurrence or dissemination of MTC stresses the
necessity of searching for new more accurate diagnostics
tools.
To the knowledge of the authors, this paper presents
the first clinical experience with Lys40(Ahx-HYNIC-
99mTc/EDDA)NH
2
]-exendin-4 in the detection of the
recurrence or dissemination of MTC.The quality of obtained
images was high; however, the image fusion was mandatory
for proper diagnosis in all reported cases.
So far, the knowledge on GLP-1 application in MTC
has emerged from experimental studies. The GLP-1 receptor
protein expression was qualitatively and quantitatively inves-
tigated in many nonneoplastic and neoplastic human tissues
with autoradiography method by Körner et al. [34]. They
foundGLP-1 receptor expression in 28%ofmedullary thyroid
carcinomas examined and in 6% of normal human thyroid
glands.GLP-1 receptor density ofMTCcellswas equal to 1,326
± 264 dpm/mg tissue of receptor-positive cases. According to
authors, medullary thyroid carcinomas exhibited a notable,
but lower, GLP-1 receptor expression compared with, for
example, pheochromocytomas. In recent paper by Gier et
al. thyroids obtained from 12 individuals were examined
for GLP-1 receptor protein by immunostaining [35]. GLP-
1 receptor immunoreactivity was detected in approximately
10–30% of the tumor cells in five of the MTC cases. How-
ever, there was clear heterogeneity, with many calcitonin
immunoreactive C cells being negative for GLP-1 receptor.
The authors stated that these studies are in agreement with
the work of Körner et al. [34].
Taking into account the GLP-1 receptor incidence and
density inMTC, it seems that GLP-1 receptor imaging should
not be used as the first-line diagnostic procedure in this group
of patients. Nevertheless in case of patients with unclear or
negative results of other imaging methods, but with clinical
symptoms of MTC recurrence and/or elevated calcitonin
concentration, this method gives the opportunity of localiza-
tion of cancer tissue. Indeed, in our group of patients, the
GLP-1 receptor imaging was carried out in two cases because
of the discrepancy between results of performed diagnostic
tests and resulted in confirmation MTC spread.
To sum up the GLP-1 receptor-expressing tumors,
among others also MTC, are prospective candidates for in
vivo targeting with Lys40(Ahx-HYNIC-99mTc/EDDA)NH
2
]-
exendin-4.
6. Conclusions
Scintigraphy with Lys40(Ahx-HYNIC-99mTc/EDDA)NH
2
]-
exendin-4 is able to detect the MTC lesions. It offers a new
diagnostic tool to assess recurrence and staging of the disease
in patients with MTC. GLP-1 receptor imaging should be
considered as an alternative choice by clinicians especially in
case of MTC patients in whom standard imaging techniques
fail. However, further studies on the subject are needed.
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